All In Biotech

Drug Trial Radar · NCT03137069

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU).

Last checked: Nov 19, 2026Latest source record: Sep 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

134

Actual

Start

May 26, 2017

Primary completion

Sep 27, 2019

Study completion Oct 25, 2019

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of GDC-0853 compared with placebo in participants with Refractory Chronic Spontaneous Urticaria (CSU) already treated with anti-histamines. Participants have the option to enter the Open-Label Extension (OLE) study after completing the 8-week treatment period.

Conditions

  • Urticaria

Interventions

  • GDC-0853Drug

    GDC-0853 will be administered orally at dosages of 50, 150 and 200mg to participants, as per the dosing schedules described above.

  • PlaceboDrug

    Matching Placebo will be administered orally, as per the dosing schedules described above.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Day 57Time frame: Baseline and Day 57

Locations

27 sites in 3 countries. Site status is shown where the registry gives one.

  • Clinical Research Center of Alabama, LLC

    Birmingham, Alabama

  • Allergy & Asthma Immunology Associates

    Scottsdale, Arizona

  • Kern Allergy Med Clinic, Inc.

    Bakersfield, California

  • Southern California Research Center

    Mission Viejo, California

  • Allergy & Asthma Consultants

    Redwood City, California

  • Integrated Research Group Inc

    Riverside, California

  • Integrated Research of Inland

    Upland, California

  • New Horizon Research Center

    Miami, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Vital Prospects Clinical Research Institute PC - CRN

    Tulsa, Oklahoma

  • Asthma, Nasal Disease, and Allergy Research Center of New England

    East Providence, Rhode Island

  • Center for Clinical Studies

    Cypress, Texas

  • Timber Lane Allergy and Asthma Research, LLC

    Burlington, Vermont

  • University of British Columbia

    Vancouver, British Columbia, Canada

  • Private Practice - Dr. Jason Ohayon

    Hamilton, Ontario, Canada

  • Lynde Institute for Dermatology

    Markham, Ontario, Canada

  • Cheema Research

    Mississauga, Ontario, Canada

  • Yang Medicine

    Ottawa, Ontario, Canada

  • Gordon Sussman Clinical Research

    Toronto, Ontario, Canada

  • Private Practice - Dr. Isabelle Delorme

    Drummondville, Quebec, Canada

  • Centre de Recherche Applique En Allergie de Quebec

    Québec, Quebec, Canada

  • Licca Clinical Research Institute

    Augsburg, Germany

  • Charite Mitte; Klinik fur Dermatologie

    Berlin, Germany

  • Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Augenheilkunde

    Dresden, Germany

  • Hautarztpraxis Mahlow

    Mahlow, Germany

  • Universitätsmedizin Johannes Gutenberg Universität

    Mainz, Germany

  • Klinik für Haut- und Geschlechtskrankheiten, Universitätsklinikum Münster

    Münster, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.